Clinical trials: Advanced Digestive System Tumor
Hepatocellular Carcinoma
Study of Sorafenib and Gemcitabine in Advanced Hepatocellular Carcinoma (HCC)
For the majority of patients, metastatic HCC is incurable and patients should be considered candidates for clinical trials when appropriate.
- Trial name
- HCC (NCT00844688)
- Testing
- sorafenib, Gemcitabine
- Where
- Pakistan
- Volunteers
- 30 people
- Sponsor
- Combined Military Hospital, Pakistan
Biliary Tract Neoplasms
Apatinib for Advanced Biliary Carcinoma
This is a phase II open-label, one-arm, single-center study of apatinib for eligible patients with advanced biliary tract carcinoma after the first-line treatment failure. A total of 55 patients is planned for enrollment.
- Trial name
- NCT03427242
- Testing
- Apatinib
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma
Phase 2 Study of Sorafenib Plus HAIC of FOLFOX vs. Sorafenib Plus HAIC of OXA for Advanced HCC
The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin plus fluorouracil/leucovorin compared with HAIC of oxaliplatin alone in patients with advanced…
- Trial name
- NCT03812770
- Testing
- Sorafenib, HAIC of FOLFOX, HAIC of OXA
- Where
- 3 sites in China
- Volunteers
- 150 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
TACE Combined With Anti-PD-1 Antibody in Patients With Advanced Hepatocellular Carcinoma: Study on Efficacy and Immune Microenvironment
This is a prospective, non-interventional, observational study evaluating the efficacy and immune microenvironment changes in Patients with Advanced Hepatocellular Carcinoma treated with TACE Combined with PD-1 Inhibitor.
- Trial name
- TASK-01-RW (NCT07100405)
- Testing
- PD-1 inhibitor, TACE
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Fudan University
Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-)
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
The purpose of this study is to learn about the safety and effects of the study medicine when given alone or together with other anti-cancer therapies. Anti-cancer therapy is a type of treatment to stop the growth of cancer.
- Conditions
- Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Colorectal Cancer, Metastatic Colorectal Adenocarcinoma
- Trial name
- NCT07318805
- Testing
- PF-08032562, Fulvestrant, Cetuximab
- Where
- 13 sites in United States
- Volunteers
- 260 people
- Sponsor
- Pfizer
Hepatocellular Carcinoma, Portal Vein Tumor Thrombus
TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTT
Hepatocellular carcinoma (HCC) with main trunk portal vein tumor thrombus (PVTT) has poor prognosis. The main lethiferous factor is the upper gastrointestinal hemorrhage by PVTT-related portal hypertension, then the second is the…
- Conditions
- Hepatocellular Carcinoma, Portal Vein Tumor Thrombus, Systemic Therapy
- Trial name
- NCT06622031
- Testing
- Transjugular intrahepatic portosystemic shunt, Lenvatinib, PD-1 inhibitor
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Sun Yat-sen University
Metastatic Hepatocellular Carcinoma, Solid Tumors
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary antitumor activity of TYRA-430 in cancers with FGF/FGFR pathway aberrations, including locally advanced/metastatic…
- Conditions
- Metastatic Hepatocellular Carcinoma, Solid Tumors, Solid Tumor, Adult, FGFR Gene Amplification
- Trial name
- SURF431 (NCT06915753)
- Testing
- TYRA-430
- Where
- 16 sites in United States, Canada and 2 more
- Volunteers
- 125 people
- Sponsor
- Tyra Biosciences, Inc
HCC - Hepatocellular Carcinoma, Chinese Herbal Medicine
Shuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat Syndrome
Primary liver cancer is a malignant tumor with a very poor prognosis. Hepatocellular carcinoma(HCC) accounts for approximately 80% of cases.
- Conditions
- HCC - Hepatocellular Carcinoma, Chinese Herbal Medicine, ICG (Indocyanine Green), Overall Survival (All-cause Mortality)
- Trial name
- DAWNbreak-120 (NCT07691645)
- Testing
- Shuganhuazhuo Formula, Targeted therapy, Immunotherapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Xiang-Qian
Cancer of the Bile Duct
Single Agent Regorafenib in Refractory Advanced Biliary Cancers
The main purpose of this study is to see if regorafenib can help control or decrease cancer size in patients with cancer of the bile duct. Researchers also want to find out if regorafenib is safe and tolerable.
- Trial name
- NCT02115542
- Testing
- Regorafenib
- Where
- 3 sites in United States
- Volunteers
- 39 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Gastric Cancer, Second-line Therapy
Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer
This study was an open, single center, prospective cohort study design. Subjects with advanced gastric cancer who had received first-line chemotherapy (cohort 1) and systematic chemotherapy combined with immunotherapy (cohort 2)…
- Trial name
- NCT07320586
- Testing
- Camrelizumab, Nab paclitaxel
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shandong Tumor Hospital
Colorectal Neoplasms
Disitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal Cancer
Among patients with colonrectal cancer, 5% were HER-2 positive, but the immunohistochemical results were mostly HER-2 2 +, which did not meet the indications of HER-2 targeting drugs.
- Trial name
- NCT05493683
- Testing
- Disitamab vedotin, Tislelizumab
- Where
- 6 sites in China
- Volunteers
- 29 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Gastric Carcinoma Stage IV
XELOX Versus FOLFOX for Advanced Gastric Cancer (AGC)
The purpose of this study is to identify the non-inferiority of the combination therapy of Capecitabine and Oxaliplatin compared with the combination therapy of Fluorouracil/Folinic acid and Oxaliplatin in patients with advanced…
- Trial name
- NCT01748851
- Testing
- XELOX, FOLFOX
- Where
- South Korea
- Volunteers
- 42 people
- Sponsor
- Dong-A University Hospital
Rectal Cancer, Low Anterior Resection Syndrome
Impact of Quality of Life in the Patients With Sleep Disturbance From Low Anterior Resection Syndrome in Advanced Rectal Cancer Patients
The preservation surgery of the anal sphincter has become a standard procedure for the treatment of rectal cancer and is now possible even when the tumor is close to the anus, thanks to the advancement of surgical techniques.
- Conditions
- Rectal Cancer, Low Anterior Resection Syndrome, Insomnia
- Trial name
- NCT06271629
- Testing
- Insomnia severity index
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Seoul National University Hospital
Esophageal Carcinoma, Neoadjuvant Chemoradiotherapy
Different Radiation Dose of Neoadjuvant Chemoradiation for Resectable Thoracic Esophageal Squamous Carcinoma
Esophageal cancer is one of the most common cancers worldwide, while more than half new cases and deaths occurred in China. Surgery is the main curative treatment for this disease, the 5-year survival of EC remains poor, since…
- Conditions
- Esophageal Carcinoma, Neoadjuvant Chemoradiotherapy, Surgery
- Trial name
- Neo-DRATEC (NCT03381651)
- Testing
- Higher dose (50.4Gy/28F) of neoadjuvant chemoradiation, Lower dose (41.4Gy/23F) of neoadjuvant chemoradiation
- Where
- 2 sites in China
- Volunteers
- 147 people
- Sponsor
- Zhejiang Cancer Hospital
MTAP-deleted Solid Tumors
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
This is a first-in-human Phase 1/2, multicenter, open-label study of S095035 as single-agent, or in combination with TNG462 in adult participants with advanced or metastatic solid tumors with homozygous deletion of MTAP who have…
- Trial name
- NCT06188702
- Testing
- S095035, TNG462
- Where
- 20 sites in United States, Australia and 5 more
- Volunteers
- 61 people
- Sponsor
- Servier Bio-Innovation LLC
Head and Neck Cancer Squamous Cell Carcinoma, Non-small Cell Lung Cancer
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
This study evaluates ADCT-301 in patients with Selected Advanced Solid Tumors. Patients will participate in a Treatment Period with 3-week cycles and a Follow-up Period every 12 weeks for up to 1 year after treatment…
- Conditions
- Head and Neck Cancer Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Gastric Cancer, Esophageal Cancer
- Trial name
- NCT03621982
- Testing
- ADCT-301, Pembrolizumab
- Where
- 9 sites in United States, Belgium and 1 more
- Volunteers
- 78 people
- Sponsor
- ADC Therapeutics S.A.
Neoplasm Metastasis
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
A First-in-Human Pharmacokinetic, Safety, and Tolerability Study of PF-07265807 as Monotherapy and in Combination in Participants with Advanced or Metastatic Solid Tumors
- Trial name
- NCT04458259
- Testing
- PF-07265807, Sasanlimab, Axitinib
- Where
- 33 sites in United States, Canada and 3 more
- Volunteers
- 88 people
- Sponsor
- Pfizer
Solid Tumors, Gastric Cancer
A First-in-Human Escalation and Expansion Study of Patients With Advanced Solid Tumors
The goal of this clinical trial is to learn if the investigational drug (JR8603) is safe and effective in treating patients with solid tumors after their initial rounds of treatment with other drugs did not work.
- Conditions
- Solid Tumors, Gastric Cancer, Esophagogastric Juction Cancer, Colorectal Cancer
- Trial name
- NCT06783569
- Testing
- JR8603
- Where
- 2 sites in China
- Volunteers
- 94 people
- Sponsor
- JiaRay Group
Pancreatic Cancer
Oxaliplatin, Gemcitabine, and Erlotinib Study in Patients With Advanced Chemo-naïve Pancreatic Cancer
The purpose of this study is to determine if the combination of Gemcitabine, Oxaliplatin and Erlotinib in the treatment of patients with pancreatic cancer will provide increased clinical benefits and improvement in their quality…
- Trial name
- GEMOX-T (NCT00636883)
- Testing
- Gemcitabine
- Where
- Saudi Arabia
- Volunteers
- 9 people
- Sponsor
- National Guard Health Affairs
Gastric Cancer
Circulating Exosomes As Potential Prognostic And Predictive Biomarkers In Advanced Gastric Cancer Patients ("EXO-PPP Study")
Exosomes are formed by inward budding of late endosomes, producing multivesicular bodies (MVBs), and are released into the environment by fusion of the MVBs with the plasma membrane.
- Trial name
- EXO-PPP (NCT01779583)
- Where
- Spain
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Hospital Miguel Servet
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.